Drug Trial Radar · NCT05515393
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
Last checked: Nov 19, 2026Latest source record: Jun 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
420
Planned (sponsor's estimate)
Start
Sep 24, 2022
Primary completion
Dec 30, 2023
Study completion Dec 30, 2023
Sponsor
- Lead sponsor
- Shijiazhuang Yiling Pharmaceutical Co. LtdIndustry
- Sponsor type
- Industry
- Collaborators
- First Affiliated Hospital, Sun Yat-Sen University
- First posted
- Aug 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Overall Design: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-exploration study. Main outcome: 1.To evaluate the efficacy and safety of XY03-EA tablets in the treatment of acute ischemic stroke.
Conditions
- Acute Ischemic Stroke
Interventions
XY03-EADrug
The sample size was 420 patients, and 140 patients were treated with XY03-EA 300 mg, 600 mg and placebo respectively. The 300-mg group took two tablets of placebo and two tablets of XY03-EA once, three times a day. The 600-mg group took four tablets of XY03-EA once, three times a day. The placebo group took four tablets of placebo once ,three times a day.
XY03-EA PlaceboDrug
XY03-EA Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of patients with Modified Rankin Scale (mRS) score ≤ 1 point at 90 days after administration.Time frame: 90 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shijiazhuang Yiling Pharmaceutical Co.,Ltd
Shijiazhuang, Hebei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.